1Strupp C,Germing U,Aivado M,et al.Thalidomide for the treatment of patiengs with myelodysplastic syndromes[J],Leukemia,2002,16 (1):126.
2Zorat F,Shetty V,Dutt D,et al.The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes[J].Br J Haematol,2001,115 (4):881-894.
3Raza A,Meyer P,Dutt D,et al.Thalidomide produces transfusion in dependence in long-standing refractory anemias of patients with myelodyplastic syndromes[J].Blood,2001,98 (4):958-965.
6Raza A. Meyer P,Dutt D, et al. Thalidomide produces trans fusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes[J]. Blood, 2001,98 (4) :958-965
7Klaelsner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor implication for clinical use elin Immu nol[J]. Immunopathol, 1996,81 : 219- 223
8Strupp C, Germing U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastic syndromes Leukemia[J]. Leukemia, 2002,16 : 1 - 6
9Gancer A, Hoelzer D. Treatment of myelodysplastic syndromes with hematopoietic growth Factors[J]. Hematol Oncolc Clin North Am,1992, (6):633-653
10JohnL C, Thompson D. Effect of recombinant human erythropoiet in combined with granulo-Cyte maerophage colony stimulating factor in thetreatment of patients with myelodysplastie Syndrome[J]. Blood, 2000,95:1175-1179
